

KRAZATI[®]
(adagrasib) | 200 mg
TABLETS

IN KRAS G12C-POSITIVE ADVANCED NSCLC
This is my non-small
REVOLUTION

This is your guide to understanding treatment after prior therapy, expectations when starting KRAZATI[®], and support that may help you along the way.

Actor portrayal.



+ For additional information and resources, visit [KRAZATI.com](https://www.krazati.com).

Important Facts About
KRAZATI[®]
(adagrasib)

This is a summary of important information that you need to know about KRAZATI. Your healthcare team can work with you to help answer any questions you may have. **Keep this document in a safe place so you can refer to it before you start taking it and during your treatment.**

Look out for the following icons as you read:



Talk to your healthcare team



Call a healthcare provider right away




Helpful information to remember

What is KRAZATI?

KRAZATI is an oral prescription medicine used to treat:

Non-small cell lung cancer (NSCLC) in adults who have:

- ✓ cancer that has spread to other parts of the body or cannot be removed by surgery, **AND**
- ✓ a tumor that has an abnormal KRAS G12C gene, **AND**
- ✓ received at least one prior medicine that works throughout your whole body (a systemic treatment)



what IS KRAZATI®?

Designed to target your specific mutation, KRAZATI helps block the abnormal KRAS G12C protein, targeting it in a way chemotherapy and immunotherapy do not.

If you have KRAS G12C-positive NSCLC that has spread to other parts of your body or can't be removed by surgery, talk to your doctor about KRAZATI if your previous treatment is no longer working.

Your healthcare provider will perform a test to make sure KRAZATI is right for you.


Designed with your specific type of cancer in mind
KRAZATI is not chemotherapy; it is a therapy that targets your disease.

Actor portrayal.

2

how KRAZATI TARGETS KRAS G12C

KRAZATI[®]
(adagrasib) 200 mg
TABLETS



KRAS is a protein found inside many cell types in our bodies. **The growth and development of cells can be controlled by KRAS, like an on/off switch.**

When the development of a genetic mutation changes the **KRAS protein to KRAS G12C, the on/off switch is stuck in an "on" position,** setting off a domino effect that can lead to cancer.

KRAZATI is designed to target and block KRAS G12C.



KRAZATI targets and helps block the KRAS G12C protein that causes tumor growth.

Important Facts About KRAZATI (cont'd)

Your healthcare team will perform a test to make sure that KRAZATI is right for you. It is not known if KRAZATI is safe and effective in children.

 **Talk to your healthcare team** for more information about what it means to have an abnormal KRAS G12C gene.

Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

**SCAN TO LEARN
MORE ABOUT HOW
KRAZATI WORKS**



QR code links to
<https://www.krazati.com/nsclc/about-krazati>



what

WERE THE STUDY RESULTS?

KRAZATI® was studied in a clinical trial of adult patients like you with KRAS G12C-positive non-small cell lung cancer (NSCLC). The trial was designed to determine how effective KRAZATI was at shrinking tumors or making them disappear, and how long tumors responded to KRAZATI.

Important Facts About KRAZATI (cont'd)

Before taking KRAZATI, what should I discuss with my healthcare team?

 Talk to your healthcare team about all of your medical conditions, including if you have:

- any heart problems, including heart failure or if you were born with long QT syndrome
- liver problems

You should not take KRAZATI if you were born with long QT syndrome or if you currently have QTc prolongation (which means your heart takes longer than usual to recharge between beats).

Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

4 Actor portrayal.

KRAZATI[®]
(adagrasib) 200 mg
TABLETS



Nearly half of patients responded to KRAZATI, meaning their tumors shrank or disappeared.



KRAZATI continued to shrink or make tumors disappear for a median response of 8.5 months, with some patients responding for over 1 year.

*112 out of 116 patients had measurable KRAS G12C-positive NSCLC when the study began and were included in the study analysis. Of the 43% (48 out of 112) of patients who responded to KRAZATI, 47 saw their tumors shrink and 1 saw all signs of cancer disappear.

KRAZATI doesn't require a break in treatment before starting, which means you can continue fighting your cancer immediately after your first-line therapy ends, without a gap in treatment.[†]

[†]Based on the KRAZATI PI; however, in the study, patients took a 2-week break after their most recent cancer treatment, including immunotherapy.




When it's time to move on from chemotherapy and/or immunotherapy, ask your healthcare provider if KRAZATI may be right for you.

5

how

DO I TAKE KRAZATI®?

Take KRAZATI exactly as your doctor tells you to take it. The recommended dosage is 600 mg twice a day.



- Taken as a pill, not an injection
- Take your prescribed dose of KRAZATI 2 times each day, at the same time each day, either with or without food
- Swallow KRAZATI pills whole. Do not chew, crush, or split pills
- Your doctor may change your dose, or temporarily or permanently stop treatment with KRAZATI if you develop certain side effects
- If you vomit after taking a dose of KRAZATI, do not take an extra dose. Take your next dose at your next scheduled time

Do not change your dose or stop taking KRAZATI unless your doctor tells you to.

IF YOU MISS A DOSE OF KRAZATI[®]:

- Take it as soon as you remember
- **By more than 4 hours?**
 - Do not take the dose; take your next dose at your next scheduled time

Do not take 2 doses of KRAZATI at the same time to make up for a missed dose.

Important Facts About KRAZATI (cont'd)

Talk to your healthcare team about all the medicines you take, including:

- prescription medicines
- over-the-counter medicines
- vitamins
- herbal supplements

Taking KRAZATI with certain other medicines may affect how KRAZATI or your other medicines work. It may also increase your chance of getting side effects from the medicines you take.

Keep a list of the medicines you take and show it to your healthcare team and pharmacist before you start taking KRAZATI or any other new medicine.

Talk to your healthcare team about anything you might be unsure of before starting treatment. There may be other topics that are important to discuss with your healthcare team that aren't in this document.

Before taking KRAZATI, what should I discuss with my healthcare team about pregnancy, breastfeeding, and fertility?

Talk to your healthcare team if:

You are pregnant or plan to become pregnant: It is not known if KRAZATI can harm your unborn baby.

You are breastfeeding or plan to breastfeed: It is not known if KRAZATI passes into your breast milk. Do not breastfeed during your treatment and for 1 week after your last dose of KRAZATI.

KRAZATI may cause fertility problems in all genders and may affect your ability to have children.

Talk to your healthcare team if having fertility problems is a concern for you.

What are the serious side effects of KRAZATI?

KRAZATI can cause serious side effects. A serious side effect is a side effect that may require medical treatment or hospitalization, cause permanent damage, or be life-threatening or sometimes even fatal. Your healthcare team may lower your dose, pause, or stop treatment with KRAZATI if you get certain side effects. The serious side effects of KRAZATI may include:

Problems in your stomach and intestines (gastrointestinal problems). Problems in your stomach and intestines can be severe when taking KRAZATI. These problems may include:

- severe nausea, vomiting, or diarrhea
- inflammation in your colon (colitis)
- bleeding in your stomach or intestines (gastrointestinal bleeding)
- certain parts of your stomach or intestines becoming narrower than normal (gastrointestinal stenosis)
- a blockage in your stomach or intestines (bowel obstruction)

Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

KRAZATI[®]
(adagrasib) 200 mg TABLETS

FOR ANSWERS TO FREQUENTLY ASKED QUESTIONS ABOUT KRAZATI, SCAN THE QR CODE BELOW



QR code links to <https://www.krazati.com/assets/buildeasy/us-commercial/krazati-dtc/en/files/downloadable-faqs.pdf>

what

ARE THE POSSIBLE SIDE EFFECTS I MAY EXPERIENCE WHILE TAKING KRAZATI®?

Stomach and intestinal (gastrointestinal) problems. Stomach and intestinal side effects, including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)¹

- **Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI**
- Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed

Changes in the electrical activity of your heart called QTc prolongation. Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death¹

- You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation
- **Before taking KRAZATI, tell your healthcare provider about all of your medical conditions:**
 - o Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat
 - o **Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI**


Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

Liver problems. Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

- Your skin or white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)

Lung or breathing problems. KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever¹

The most common side effects of KRAZATI included:



Pay attention to how your body feels. If you experience any side effects, it's important to talk to your healthcare provider right away.

what

TIPS ARE THERE FOR MANAGING SIDE EFFECTS?

Tips for managing side effects



DIARRHEA

- Drinking fluids may help you stay hydrated
- Eating smaller meals with foods that might be easy on your stomach, such as those high in potassium and sodium, may help replace what your body has lost
- Discuss possible treatments for this symptom with your doctor

NAUSEA AND VOMITING

- Drink plenty of fluids—water and clear liquids
- Eat smaller, more frequent meals. Nausea may be worse on an empty stomach
- Pay attention to which foods bother your stomach and try to avoid them (ie, greasy, fried, sweet, or spicy foods)
- Talk to your doctor about taking anti-nausea medicine

TIREDNESS/FATIGUE

- Track your energy level throughout the day, and have it on-hand to discuss with your doctor
- Balance rest and activity, prioritizing your most necessary activities for when you may have the most energy
- Staying hydrated and eating foods high in protein may increase your energy levels
- If feelings/emotions are disturbing your sleep, talk to your doctor about a referral to a specialist

The tips provided here are for informational purposes only and are not meant to replace a physician's medical advice. Please contact your healthcare team if you are experiencing these side effects and ask your doctor if these tips may be right for you.

Actor portrayal.

 Bristol Myers Squibb®
Access Support® >

At Bristol Myers Squibb, We Provide Support With Purpose

You are the reason behind what we do. BMS Access Support is committed to helping you access your prescribed BMS medication. If you were prescribed KRAZATI® (adagrasib) and enroll in BMS Access Support, the program may be able to provide:



Coverage Assistance

Upon your request, BMS Access Support may be able to help you review your insurance benefits and understand your coverage for KRAZATI.*

If your insurer requires prior authorization, BMS Access Support may be able to provide you and your doctor information about this requirement.

In the event of a coverage delay or denial, you may be eligible for a bridge program to cover your treatment for KRAZATI.†



Financial Support

If you are an eligible commercially-insured patient, you may pay as little as \$0 per one-month supply.‡

If you are insured through a government program or you do not have insurance, BMS Access Support can provide you with information regarding independent charitable foundations.‡



Educational Resources

BMS Access Support offers a library of resources that can help you better understand your healthcare coverage and guide you through steps in your treatment journey.

A Free Trial Offer may be available for KRAZATI†

*The accurate completion and submission of reimbursement and coverage-related documentation to the patient's insurance plan is the responsibility of the provider and patient. Bristol Myers Squibb and its agents cannot guarantee coverage for any medication or treatment.

†Restrictions apply. Please see full Terms and Conditions, including complete eligibility requirements in the pocket.

‡It is important to note that charitable foundations are independent from Bristol-Myers Squibb Company and have their own eligibility criteria and evaluation process. Bristol Myers Squibb cannot guarantee that a patient will receive assistance.

We're here for you.
Coverage assistance,
educational resources,
and financial support
options may be
available through
BMS Access Support®



Call BMS Access Support
1-800-861-0048, 8 AM to 8 PM ET,
Monday-Friday



Visit www.BMSAccessSupport.com

Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

Important Facts About KRAZATI® (cont'd)

Problems in your stomach and intestines (gastrointestinal problems) (cont'd)

 **Call a healthcare provider right away** if you have any of the following signs or symptoms of problems in your stomach and intestines:

- vomiting six or more times (separated by 5 minutes) in 24 hours
- vomit with blood in it or vomit that looks like coffee grounds
- nausea that prevents you from eating and drinking enough
- pain in your stomach (abdominal) area
- trouble urinating or dark urine
- dark-colored stool or stool with blood in it
- diarrhea where you have at least 7 more stools per day than usual and have trouble holding in your bowel movements (fecal incontinence)
- feeling dizzy, lightheaded, or weak
- shortness of breath
- feeling like your heart is beating faster than normal or fluttering (rapid pulse)

Your healthcare team may prescribe you a medicine (such as an anti-diarrheal or anti-nausea medicine) to help treat possible side effects related to your stomach and intestines.

Changes to the way your heart beats (called QTc prolongation). Taking KRAZATI may cause changes to the way your heart beats, including causing your heart to take longer to recharge between beats (this is called QTc prolongation). QTc prolongation may increase your chance of developing an irregular heartbeat that may be life-threatening and lead to sudden death. For example, it may cause a particular kind of very fast heartbeat called Torsades de Pointes.

Before and during your treatment with KRAZATI, your healthcare team may:

- give you a test called an electrocardiogram (ECG) to measure the electrical activity of your heart
- give you blood tests to measure how much of certain kinds of minerals (electrolytes) like potassium and magnesium are in your blood

Your healthcare team is more likely to give you the above tests if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or are taking another medicine that may lead to QTc prolongation.

 **Call a healthcare provider** if you have any of the following signs or symptoms:

- feeling dizzy, lightheaded, or weak
- an abnormal heartbeat (arrhythmia) such as your heart beating faster than usual, slower than usual, or beating in an irregular pattern

Important Facts About KRAZATI (cont'd)

Problems with your liver. It is common to get abnormal results on liver blood tests when you take KRAZATI. These abnormal results may sometimes indicate severe problems with your liver. Your healthcare team will do blood tests before and during your treatment with KRAZATI to check how your liver is working.

 **Call a healthcare provider** if you have any of these signs or symptoms:

- yellowing of your skin or the white parts of your eyes (jaundice)
- dark-colored urine
- light-colored stool
- feeling tired or weak
- unexplained nausea or vomiting
- bleeding or bruising more easily than normal
- losing your appetite
- pain, aching, or tenderness on the right side of your stomach (abdominal) area

Problems with your lungs or breathing (lung inflammation or pneumonitis): KRAZATI may cause inflammation in your lungs, which may be severe or serious and can lead to death.

 **Call a healthcare provider or get emergency medical help right away** if you have any of these signs or symptoms:

- new or worsening shortness of breath
- new or worsening cough
- fever

What are the most common side effects of KRAZATI?

The most common side effects of KRAZATI when it is taken on its own for **non-small cell lung cancer (NSCLC)** include:

- nausea
- diarrhea
- vomiting
- feeling tired
- pain in your muscles and bones
- kidney problems
- swelling in any part of your body
- feeling less hungry than usual (decreased appetite)
- trouble breathing

It is also common to get abnormal results on certain blood tests while you are taking KRAZATI, whether you are taking it on its own or in combination with cetuximab. While you are taking KRAZATI, your healthcare team will give you blood tests to monitor you for abnormal blood test results and will treat you if needed.

The common and serious side effects mentioned in this document are not all the possible side effects of KRAZATI.

Please see additional Important Safety Information on pages 14 and 15 and the Patient Information in the accompanying Full Prescribing Information in pocket.



Important Facts About KRAZATI® (cont'd)

Problems in your stomach and intestines (gastrointestinal problems)(cont'd)

 **Talk to your healthcare team for more information or advice about side effects.** You are encouraged to report side effects to the FDA at www.fda.gov/medwatch or calling 1-800-FDA-1088.

What does KRAZATI look like and what are its ingredients?

KRAZATI comes as a white or off-white oval-shaped tablet, each containing a 200-mg dose of its active ingredient. Each tablet has the number "200" stamped into the surface on one side, and a stylized "M" stamped into the other side.



Note: Image does not represent actual tablet sizes

Ingredients:

- **Active:** adagrasib
- **Inactive:** colloidal silicon dioxide, crospovidone, magnesium stearate (vegetable sourced), mannitol, microcrystalline cellulose, hypromellose, maltodextrin, medium chain triglycerides (vegetable sourced), polydextrose, talc, and titanium dioxide

How should I take KRAZATI?

Take KRAZATI exactly as your healthcare team tells you. Do not change how much you take or stop taking KRAZATI unless a healthcare provider tells you to.

The recommended dose of KRAZATI is three tablets (a 600-mg dose) by mouth twice a day, at about the same time each day. If you are taking KRAZATI for colon or rectal cancer, your healthcare team will also give you a medicine called cetuximab through a vein in your arm (as an intravenous (IV) infusion) every week or every other week. Your healthcare team may need to change how much KRAZATI you take, or pause or stop your treatment with KRAZATI (and cetuximab, if you are taking it), if you have certain side effects.

- ✓ **Do** take KRAZATI by mouth (orally) twice a day, around the same time each day
- ✓ **Do** take KRAZATI with or without food
- ✓ **Do** swallow KRAZATI tablets **whole**
- ✗ **Do not** chew, crush or split tablets
- ✗ **Do not** take broken or damaged tablets

Important Facts About KRAZATI (cont'd)

What if I vomit or miss a dose of KRAZATI?

Do not take an extra dose.

- **If you vomit after taking a dose** of KRAZATI, do not take an extra dose. Take your next dose at your next scheduled time
- **If you miss a dose** of KRAZATI and it has been:
 - **Less than four hours** since you were supposed to take it, take the dose
 - **More than four hours** since you were supposed to take your dose, skip that dose. Just take your next dose of KRAZATI at your next scheduled time. Do not take two doses at the same time to make up for a missed dose



Setting an alarm clock or a calendar notification is a great way to help you remember to take your medication.

What if I take too much KRAZATI?

 **Call a healthcare provider or Poison Health Line at (1-800-222-1222), or go to the nearest hospital emergency room right away.**

How should I store KRAZATI?

Keep your KRAZATI tablets in their original containers. These containers are child-resistant and include a packet of desiccant (drying agent) that keeps tablets dry.

- **Do not** remove the packet of desiccant (drying agent) from the container
- **Do not** eat or swallow the desiccant

Store tablets at **room temperature** between 68°F to 77°F (20°C to 25°C).

Keep KRAZATI and all medicines out of reach of children.

What else should I know about KRAZATI?

Do not use KRAZATI for any condition other than what your healthcare team has prescribed it for. Healthcare teams may sometimes prescribe KRAZATI for purposes other than those mentioned in this document.

Do not give KRAZATI to other people, even if they have the same symptoms as you. It may harm them.

Ask your healthcare team for the information about KRAZATI that is written for healthcare providers if you would like.

Please see additional Important Safety Information on pages 12 and 13 and the Patient Information in the accompanying Full Prescribing Information in pocket.

KRAZATI[®]: Things to remember

Actor portrayal.



- 1 KRAZATI is different because it targets your cancer in a way chemotherapy and immunotherapy do not**
KRAZATI is a targeted therapy designed to target KRAS G12C to help fight specific proteins that help cause tumors to grow and spread throughout the body.
- 2 Nearly half (43%) of patients saw tumors shrink or disappear**
Out of 112 people, 1 person saw all signs of cancer disappear and 47 people saw their tumors shrink.*
Important Considerations: The approval of KRAZATI in these patients is based on a study that measured the size of tumor shrinkage.
- 3 KRAZATI doesn't require a break in treatment before starting, so you can continue fighting your cancer immediately after first-line therapy ends[†]**

*In a clinical trial of 116 adults with *KRAS* G12C NSCLC that has spread or cannot be removed by surgery.
[†]Based on the KRAZATI PI; however, in the study, patients took a 2-week break after their most recent cancer treatment, including immunotherapy.

KRAZATI may cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of your heart called QTc prolongation, liver problems, and lung or breathing problems.

The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, and trouble breathing.

Important Facts About KRAZATI (cont'd)

i For more information, please see the accompanying US Full Prescribing Information and Patient Information for KRAZATI. Talk to your healthcare team for more information about this medication.

Please see additional Important Safety Information on pages 12-15 and the Patient Information in the accompanying Full Prescribing Information in pocket.

References: **1.** KRAZATI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2024. **2.** Docetaxel [package insert]. Pfizer Inc. 2022. **3.** Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. *JCI Insight*. 2018;3(15):e120858. **4.** Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a *KRAS*^{G12C} mutation. *N Engl J Med*. 2022;387(2):120-131. **5.** Gray JE, Hsu H, Younan D, et al. Real-world outcomes in patients with *KRAS* G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond. *Lung Cancer*. 2023;181:107260. **6.** Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. *Genes Cancer*. 2011;2(3):344-358. **7.** National Cancer Institute. Diarrhea and Cancer Treatment. Updated May 16, 2025. Accessed August 27, 2025. <https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea> **8.** National Cancer Institute. Nausea and Vomiting and Cancer Treatment. Updated May 9, 2025. Accessed August 27, 2025. <https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting> **9.** National Cancer Institute. Cancer Fatigue. Updated September 20, 2024. Accessed August 27, 2025. <https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue>



© 2025 Mirati Therapeutics, Inc., a Bristol Myers Squibb company.
KRAZATI[®] and the related logo are registered trademarks of Mirati Therapeutics, Inc. Access Support is a registered trademark of Bristol-Myers Squibb Company.
1914-US-2500083 10/25